Study for advanced ER+ HER2− breast cancer after CDK4/6 therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult woman (18 or older).
- Your breast cancer is ER-positive and HER2-negative, confirmed by lab pathology testing.
- Your cancer is locally advanced (can’t have curative local treatment) or metastatic/recurrent.
- You have already taken a CDK4/6 inhibitor (and the treatment didn’t stop the cancer).
- You have at least one measurable tumor spot that can be tracked on a scan.
- Your general health labs (blood counts, liver, kidney) are within required limits, and you feel well enough (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This study tests two treatments for advanced breast cancer that has stopped responding to a common class of drugs. It combines a targeted pill (famitinib) with an experimental antibody-drug treatment (SHR-A1811) to see if the combination works better than the antibody-drug alone.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.